HOOK: HOOKIPA Pharma, Inc. Price to Sales
The current P/S of HOOKIPA Pharma Inc. (HOOK) demonstrates volatility dependent on the scalability of biocomponents and successes in cancer therapy. The 0.90 indicator determines the magnitude of the metric, while capitalization is based on payments from Gilead for vaccines. Business stability is supported by diversified air transport, which prevents supply disruptions of medications for patients with HIV and hepatitis.
Metric breakdowns and analytics for HOOKIPA Pharma Inc. (HOOK)
- stock price and consensus target price:
- market capitalization information:
- shareholders' equity book value data:
- debt obligations and liquidity statistics:
- earnings and valuation multiples information:
HOOK - Net Income|Expected Net Income HOOKIPA Pharma Inc.|HOOK - Price to Earnings Ratio|Price to Expected Earnings Ratio hookipapharma.com|HOOK - PEG Multiple|Business Value to Operating Income Before Depreciation HOOKIPA|HOOK - Operating profit EBITDA|Net earnings per share (EPS TTM) HOOKIPA Pharma|HOOK - Earnings per share for the last twelve months|Year-over-year earnings per one share growth for the last 12 months hookipapharma.com|HOOK - Earnings per share growth in current year|Expected earnings per share growth for next year HOOKIPA Pharma Inc.
- total revenue and sales volume data:
General company analysis:HOOK, HOOKIPA Pharma, Inc.
The strong pricing power of HOOKIPA Pharma Inc. (HOOK) within the HPV tumor therapy segment renders revenue resilient to market volatility, which is critical for assessing capitalization via the P/S multiple. By analyzing the divergence of the P/S ratio from its historical average, an investor compares the business's market value with the volume of generated revenue to determine the premium paid for unique virus reprogramming technologies and capital liquidity.
Competitors of HOOKIPA Pharma Inc.
argenx.com - Market Cap to Revenue Ratio|P/S Multiple BNTX (BioNTech)|Abivax Pharma (ABVX) - Price to Sales|ADMA Bio - P/S Multiple|Market Capitalization-to-Revenue Ratio PTGX (Protagonist Corp)|Immunovant, Inc. (IMVT) - Price-to-Revenue Ratio|Price to Sales kiniksa.com (KNSA)|Price-to-Revenue Ratio Grifols|Price to Sales Adaptive Biotech ADPT|Price-to-Revenue Ratio Celldex (CLDX)|P/S Multiple Aurinia Corp (AUPH)|P/S Multiple BCRX (BioCryst)|Price-to-Revenue Coefficient veratx.com (VERA)|DNTH - Price-to-Revenue Ratio|Price-to-Sales Ratio PHVS|ABCL: P/S Multiple|Tourmaline (TRML) - P/S Multiple|Market Cap to Revenue PGEN|PHAR: Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Nektar Therapeutics Inc. (NKTR)|UPB: Price-to-Sales Ratio|P/S Multiple ZBIO (Zenas Biopharma, Inc.)|Market Capitalization-to-Revenue Ratio IMNM|Gossamer Bio, Inc. - P/S Multiple|KALV - P/S Multiple|Septerna (SEPN) - Price-to-Revenue Ratio|Pieris Pharma - Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Savara Corp|Market Cap to Revenue Rigel Corp (RIGL)|P/S Multiple ANAB|P/S Multiple astriatx.com (ATXS)|enGene - Market Cap to Revenue|Market Capitalization-to-Revenue Ratio RAPT|Aerovate - P/S Multiple|Price-to-Revenue Coefficient Aclaris Therapeutics, Inc ACRS|Kyverna Therapeutics (KYTX) - Price-to-Revenue Ratio|Market Cap to Revenue Ratio TLSA|CABA (Cabaletta Bio) - P/S Multiple|Market Cap to Revenue Ventyx Biosciences Inc. (VTYX)|Market Cap to Revenue THTX (Theratechnologies Inc)|Price-to-Revenue Coefficient Avalo Therapeutics Inc|P/S Multiple ELDN (Eledon Pharmaceuticals)|Market Capitalization-to-Revenue Ratio AGEN|CLYM - Price-to-Revenue Ratio|Price to Sales Zura Bio Ltd|aTyr (ATYR) - Price-to-Revenue Ratio|Price to Sales Adagene Inc. (ADAG)|Price-to-Revenue Ratio ImageneBio|P/S Multiple Shattuck Therapeutics|Price-to-Revenue Ratio Equillium, Inc. (EQ)|CNTB: Price-to-Sales Ratio|P/S Multiple IMUX (Immunic)|Market Capitalization-to-Revenue Ratio ATRA|InflaRx GmbH - P/S Multiple|XFOR - P/S Multiple|adicetbio.com (ACET) - Price-to-Revenue Ratio|Celularity - Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio INmune Bio Corp|Market Cap to Revenue Barinthus Biotherapeutics Corp (BRNS)|P/S Multiple KZR|P/S Multiple sabbiotherapeutics.com (SABS)|Akari Therapeutics Plc - Market Cap to Revenue|Market Capitalization-to-Revenue Ratio ENLV|Q32 Bio Corp - P/S Multiple|Price-to-Revenue Coefficient GeoVax Corp GOVX|Edesa Biotech, Inc. (EDSA) - Price-to-Revenue Ratio|Market Cap to Revenue ibioinc.com|Price-to-Revenue Ratio Carisma Therapeutics Inc|Market Cap to Revenue XTL Biopharmaceuticals Ltd (XTLB)|Market Cap to Revenue BOLT (Bolt Biotherapeutics)|P/S Multiple hcwbiologics.com (HCWB)|Price-to-Revenue Ratio Aptevo Therapeutics Inc. APVO|AIM: Market Cap to Revenue Ratio|Aditxt Corp - P/S Multiple|Price to Sales GRI Bio Inc|XRTX: P/S Multiple|Vyome Therapeutics - Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Revelation Biosciences|Price to Sales indaptusrx.com INDP|Price-to-Revenue Ratio Scinai Immunotherapeutics Ltd. (SCNI)|CALI - Price to Sales|Price-to-Revenue Ratio Affimed N.V. AFMD|P/S Multiple Allakos Inc ALLK|IGM Bio - P/S Multiple|Price-to-Revenue Coefficient iteostherapeutics.com ITOS|Ocean Biomedical (OCEA) - Price-to-Revenue Ratio|Price-to-Sales Ratio TCBP (TC BioPharm (Holdings) Plc)|THRD (Third Harmonic Bio, Inc) - P/S Multiple
